Information Provided By:
Fly News Breaks for January 3, 2017
CDXC
Jan 3, 2017 | 07:09 EDT
Rodman & Renshaw analyst Raghuram Selvaraju started ChromaDex with a Buy rating and $6 price target. The company's proprietary plant chemical-based technology platforms could provide "significant upside," the analyst contends.
News For CDXC From the Last 2 Days
There are no results for your query CDXC